Compare American Electric Power Company Inc (AEP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs Regeneron Pharmaceuticals Inc — how do they compare? American Electric Power Company Inc trades at $135.88 (market cap $74.83B), while Regeneron Pharmaceuticals Inc trades at $663.7 (market cap $70.90B). The key difference: American Electric Power Company Inc and Regeneron Pharmaceuticals Inc are close in size by market cap, and American Electric Power Company Inc pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| AEP | REGN | |
|---|---|---|
Market Cap | $74.83B | $70.90B |
Sector | Utilities | Health |
52-Week High | $138.69 | $812.27 |
52-Week Low | $103.96 | $542.52 |
Enterprise Value | $126.09B | $64.85B |
Dividend Yield | 2.76% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $137.53, down 0.71% on the day, with strong analyst support (64% buy ratings) and a $142.82 consensus price target. The stock shows bullish technical momentum with recent earnings beats and robust revenue growth, climbing from $19.7B in 2024 to $21.9B in 2025. AEP benefits from AI-driven electricity demand and a $78B capital plan for grid expansion.
Outlook remains positive given AEP's strategic positioning in energy infrastructure, though risks include high capital expenditures and debt levels. The current valuation at 20.12x P/E appears reasonable for a utility with stable earnings growth and dividend payments, supporting a constructive view for long-term investors.
Regeneron (REGN) trades at $676.23, up 3.36% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $9.47 exceeding the $8.91 forecast. Revenue grew to $14.34B in 2025, with a net income margin of 29.65%. Recent FDA acceptance of cemdisiran for gMG and inclusion in a manufacturing review pilot program highlight positive regulatory developments.
Outlook remains positive given earnings momentum and analyst consensus, but risks include regulatory scrutiny and competitive pressures. The consensus price target of $778.29 implies 15% upside, supported by 32 buy ratings and no sells. However, legal investigations and reliance on key drug portfolios warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
